On August 14, 2020 Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, reported that the U.S. Securities and Exchange Commission ("SEC") has declared effective the Company’s registration statement on Form F-1 (the "Registration Statement") relating to the permitted resale of up to 12,695,445 ordinary shares, nominal value 0.1p each, in the Company ("Ordinary Shares") represented by 2,539,091 American Depositary Shares (the "ADSs") held by certain stockholders of the Company named in the registration statement that are issuable upon the exercise of previously issued warrants as follows (Press release, Midatech Pharma, AUG 14, 2020, View Source [SID1234563638]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

·3,150,000 Ordinary Shares represented by 630,000 ADSs issuable upon exercise of warrants at $6.25 per ADS. These warrants were issued pursuant to a US Registered Direct Offering in October 2019;

·9,545,455 Ordinary Shares represented by 1,818,182 ADSs issuable upon exercise of warrants at $2.05 per ADS. These warrants were issued pursuant to a US Registered Direct Offering in May 2020; and

·454,549 Ordinary Shares represented by 90,909 ADSs issuable upon exercise of warrants at $2.0625 per ADS. These warrants were also issued pursuant to a US Registered Direct Offering in May 2020.

In addition, in May 2020, warrants were issued to certain UK investors in respect 3,213,957 Ordinary Shares exercisable at £0.34 per share. These warrants became exercisable upon the effectiveness of the Registration Statement.

The Registration Statement, while effective, allows the stockholders named in the Registration Statement to publicly resell the ADSs or Ordinary Shares. The Company will not receive any proceeds from the sale of the ADSs or Ordinary Shares by the stockholders. Upon the cash exercise of the warrants, the Company will receive the exercise price of the warrants.

The Registration Statement may be accessed through the SEC’s website at www.sec.gov. A copy of the prospectus relating to the offering may also be accessed through the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.